Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This prospective, randomized, active-controlled, parallel arm study compares the safety and
financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A
novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for
cardiac operations.